Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sun-Kyeong Park, Jae-A Park, So-Young Yang, Ju-Young Shin & Hyein Koh. (2020) The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data. Current Medical Research and Opinion 36:11, pages 1825-1833.
Read now
Read now
Nicole Princic, Ayal Aizer, Derek H. Tang, David M. Smith, William Johnson & Aditya Bardia. (2019) Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Current Medical Research and Opinion 35:1, pages 73-80.
Read now
Read now
Nicole Meyer, Yanni Hao, Pamela Landsman-Blumberg, William Johnson, Paul Juneau & Jaqueline Willemann Rogerio. (2015) Health care costs and utilization of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents. Comparative Effectiveness Research 5, pages 21-34.
Read now
Read now
Articles from other publishers (5)
Hsuan-Ming Chen, Jin-Hua Chen, Shao-Chin Chiang, Yi-Chun Lin & Yu Ko. (2021) An evaluation of the healthcare costs of metastatic breast cancer. Medicine 100:43, pages e27567.
Crossref
Crossref
Christine Leopold, Anita K. Wagner, Fang Zhang, Christine Y. Lu, Craig C. Earle, Larissa Nekhlyudov, Dennis Ross-Degnan & J. Frank Wharam. (2018) Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. Breast Cancer Research and Treatment 171:2, pages 449-459.
Crossref
Crossref
Guy Jerusalem, Patrick Neven, Nina Marinsek, Jie Zhang, Ravi Degun, Giancarlo Benelli, Stephen Saletan, Jean-François Ricci & Fabrice Andre. (2015) Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe. BMC Cancer 15:1.
Crossref
Crossref
Nicole Meyer, Yanni Hao, Xue Song, Nianwen Shi, William Johnson, Jaqueline Willemann Rogerio & Denise A. Yardley. (2014) Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents. International Journal of Breast Cancer 2014, pages 1-12.
Crossref
Crossref
Alberto J. Montero, Sara Eapen, Brian Gorin & Paulette Adler. (2012) The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Research and Treatment 134:2, pages 815-822.
Crossref
Crossref